Whitehawk Therapeutics (WHWK) EBITDA (2010 - 2026)
Whitehawk Therapeutics (WHWK) posted quarterly EBITDA of -$23.5 million for Q1 2026, down 54.57% year-over-year from -$51.8 million in Q1 2025, and up 5.48% quarter-over-quarter from -$24.9 million in Q4 2025.
Whitehawk Therapeutics (WHWK) EBITDA (2010 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported EBITDA for 17 consecutive years, with -$23.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA fell 54.57% year-over-year to -$23.5 million; the TTM figure through Mar 2026 stood at -$122.7 million (down 94.26% YoY), while the FY2025 annual figure was -$114.4 million, down 69.59% from the prior year.
- EBITDA grew to -$23.5 million in Q1 2026 per WHWK's latest filing, from -$24.9 million in the prior quarter.
- Across five years, EBITDA topped out at -$13.4 million in Q3 2024 and bottomed at -$54.7 million in Q2 2025.
- Historically, EBITDA has averaged -$20.0 million across 5 years, with a median of -$17.8 million in 2023.
- On a YoY basis, EBITDA climbed as much as 82.78% in 2022 and fell as far as 373.81% in 2022.
- Whitehawk Therapeutics' EBITDA stood at -$15.5 million in 2022, then slipped by 14.49% to -$17.7 million in 2023, then fell by 6.97% to -$18.9 million in 2024, then tumbled by 31.34% to -$24.9 million in 2025, then advanced by 5.48% to -$23.5 million in 2026.
- Business Quant data shows WHWK's EBITDA at -$23.5 million in Q1 2026, -$24.9 million in Q4 2025, and -$19.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - | -18.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.11 Mn |
| Mar 31, 2026 | -23.52 Mn |
| Dec 31, 2025 | -24.89 Mn |
| Sep 30, 2025 | -19.55 Mn |
| Jun 30, 2025 | -54.75 Mn |
| Mar 31, 2025 | -15.22 Mn |
| Dec 31, 2024 | -18.95 Mn |
| Sep 30, 2024 | -13.41 Mn |
| Jun 30, 2024 | -15.58 Mn |
| Mar 31, 2024 | -19.51 Mn |
| Dec 31, 2023 | -17.71 Mn |
| Sep 30, 2023 | -17.85 Mn |
| Jun 30, 2023 | -19.55 Mn |
| Mar 31, 2023 | -16.83 Mn |
| Dec 31, 2022 | -15.47 Mn |
| Sep 30, 2022 | -15.04 Mn |
| Jun 30, 2022 | -18.36 Mn |
| Mar 31, 2022 | -13.81 Mn |
| Dec 31, 2021 | -15.95 Mn |
| Sep 30, 2021 | -87.31 Mn |